A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
The primary purpose of this study is to demonstrate the superiority of UCB0022 as an adjunctive treatment to stable dose of standard-of-care (SoC) (including at least levodopa therapy) over placebo with regard to motor fluctuations time spent in the OFF state (OFF time) in study participants with advanced Parkinson\'s Disease (PD).
Epistemonikos ID: 2dbb09933d021c8b2b7af7a9ae89bd9c33a6e207
First added on: May 15, 2024